Results 111 to 120 of about 32,390 (296)
ESC Heart Failure, Volume 12, Issue 2, Page 1386-1397, April 2025.Sequeira et al. reveal how the glucagon‐like peptide‐1 receptor agonist (GLP‐1‐RA) semaglutide restores cardiomyocyte function in rats subjected to a high‐fat/high‐fructose diet (HFD). Employing fluorescence‐ and patch‐clamp technology in isolated cardiac myocytes, they demonstrate that semaglutide reverses HFD‐induced activation of L‐type calcium ...
Vasco Sequeira +12 more
wiley +1 more source
Reframing the role of glucagon‐like peptide 1 receptor agonists in cardiovascular medicine
ESC Heart Failure, Volume 12, Issue 2, Page 923-926, April 2025.
Riccardo M. Inciardi +3 more
wiley +1 more source
ESC Heart Failure, Volume 12, Issue 2, Page 1132-1140, April 2025.Abstract The main purpose of this project was to capture experts' opinion on hyperkalaemia management and form best practice recommendations for cardiorenal patients in Greece. A steering committee of nephrologists and cardiologists developed 37 statements. An online questionnaire completed by 32 experts in cardiorenal management in Greece.
Christina Chrysohoou +3 more
wiley +1 more source
Cardiologia HungaricaHeart failure (HF) is currently one of the most important public health problems. Heart failure with preserved ejection fraction (HFpEF) is a highly heterogeneous disease characterized by normal or near-normal left ventricular ejection fraction ...
Arnold Péter Ráduly +3 more
doaj +1 more source
Performance of non-invasive myocardial work to predict the first hospitalization for de novo heart failure with preserved ejection fraction (HFpEF) [PDF]
, 2022 Pasquale Paolisso +14 more
openalex +1 more source
Cilostazol in patients with heart failure and preserved ejection fraction—The CLIP‐HFpEF trial
ESC Heart Failure, Volume 12, Issue 2, Page 1437-1446, April 2025.• Cilostazol is an oral PDE‐3 inhibitor that may have advantageous effects in heart failure with preserved ejection fraction (HFpEF). • Cilostazol significantly improved short‐term heart failure‐related health status scores (KCCQ‐12) and NT‐proBNP levels when compared to placebo.
Norman Aiad +9 more
wiley +1 more source
P3737Left ventricular filling pressure estimation in HFpEF, is echocardiography reliable? [PDF]
, 2018 Minh Tam Bailly +5 more
openalex +1 more source
Adropin protects against cardiac remodeling and metabolic dysfunction in a mouse model of HFpEF
bioRxivCardiometabolic heart failure with preserved ejection fraction (HFpEF) is a heterogenous metabolic disease, which in the heart presents as left ventricle diastolic dysfunction, ventricular stiffness, and myocardial structural remodeling.
B. Mushala +16 more
semanticscholar +1 more source